中国实用医刊
中國實用醫刊
중국실용의간
CENTRAL PLAINS MEDICAL JOURNAL
2013年
21期
6-8
,共3页
麻疹孪生球菌%儿童%脑膜炎
痳疹孿生毬菌%兒童%腦膜炎
마진련생구균%인동%뇌막염
Gemella mobillorum%Children%Meningitis
目的 提高对儿童麻疹孪生球菌脑膜炎的认识.方法 对3例麻疹孪生球菌脑膜炎患儿的临床资料进行回顾性分析并复习相关文献.结果 3例患儿均以发热、呕吐起病,1例伴有抽搐.辅助检查示血象增高,中性粒占优势,血沉、C-反应蛋白(CRP)、降钙素原(PCT)增高,免疫功能低下.1例有先天性耳聋以及脑脊液鼻漏,2例有既往颅内感染病史.2例脑脊液培养示麻疹孪生球菌生长,1例血液培养示麻疹孪生球菌生长.给予美罗培南(或者头孢类抗生素)联合利福霉素治疗后,痊愈.结论 儿童麻疹孪生球菌脑膜炎易发生于免疫低下和血脑屏障不完整的的儿童,预后相对较好.
目的 提高對兒童痳疹孿生毬菌腦膜炎的認識.方法 對3例痳疹孿生毬菌腦膜炎患兒的臨床資料進行迴顧性分析併複習相關文獻.結果 3例患兒均以髮熱、嘔吐起病,1例伴有抽搐.輔助檢查示血象增高,中性粒佔優勢,血沉、C-反應蛋白(CRP)、降鈣素原(PCT)增高,免疫功能低下.1例有先天性耳聾以及腦脊液鼻漏,2例有既往顱內感染病史.2例腦脊液培養示痳疹孿生毬菌生長,1例血液培養示痳疹孿生毬菌生長.給予美囉培南(或者頭孢類抗生素)聯閤利福黴素治療後,痊愈.結論 兒童痳疹孿生毬菌腦膜炎易髮生于免疫低下和血腦屏障不完整的的兒童,預後相對較好.
목적 제고대인동마진련생구균뇌막염적인식.방법 대3례마진련생구균뇌막염환인적림상자료진행회고성분석병복습상관문헌.결과 3례환인균이발열、구토기병,1례반유추휵.보조검사시혈상증고,중성립점우세,혈침、C-반응단백(CRP)、강개소원(PCT)증고,면역공능저하.1례유선천성이롱이급뇌척액비루,2례유기왕로내감염병사.2례뇌척액배양시마진련생구균생장,1례혈액배양시마진련생구균생장.급여미라배남(혹자두포류항생소)연합리복매소치료후,전유.결론 인동마진련생구균뇌막염역발생우면역저하화혈뇌병장불완정적적인동,예후상대교호.
Objective To improve the awareness of the Gemella mobillorum meningitis in children.Methods The clinical data of 3 cases of children Gemella mobillorum meningitis were retrospectively analyzed and the related literatures were reviewed.Results All the onset of the 3 patients were fever and vomiting,1 patient with convulsions.The auxiliary examination of all the 3 patients showed that the white blood cell count increased,and the neutrophil increased prominently.ESR,CRP,PCT increased while the immunologic function decreased.One patient had congenital deafness,and cerebrospinal fluid rhinorrhea.In 2 patients,the cerebrospinal fluid culture showed that the Gemella mobillorum growth.In 1 patient,the blood cultures showed that the Gemella mobillorum growth.After be given the united anti-infection treatment with rifamycin and meropenem (or cephalosporins),all the 3 patient were healed.Conclusions The Gemella mobillorum meningitis in children prone to occure in the condition of the immunosuppression and incomplete blood-brain barrier.And the prognosis is relatively good,compared with the adult.